Related Experiment Videos
Ara-C: cellular and molecular pharmacology
1Department of Medicine, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298, USA.
Advances in Cancer Research
|October 24, 1997
Summary
Cytosine arabinoside (ara-C) effectively treats leukemia by converting to ara-CTP, which damages DNA and induces cancer cell death. Understanding these mechanisms can improve leukemia therapies.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Cytosine arabinoside (ara-C) is a key antineoplastic agent for acute leukemia and hematopoietic malignancies.
- Its efficacy relies on intracellular conversion and interaction with DNA synthesis pathways.
Purpose of the Study:
- To elucidate the multi-level mechanisms governing ara-C's cytotoxicity in neoplastic cells.
- To identify factors influencing ara-C sensitivity and resistance.
Main Methods:
- The study reviews the biochemical and molecular processes involved in ara-C's action.
- It examines the conversion of ara-C to its active form, ara-CTP.
- Analysis of DNA polymerase interactions, DNA incorporation, and apoptosis induction pathways.
Main Results:
- Ara-C's activity is dependent on its conversion to ara-CTP, influenced by transport, phosphorylation, and metabolite competition.
- Ara-CTP interferes with DNA polymerases and is incorporated into DNA, causing fragmentation and chain termination.
- Apoptosis is triggered when DNA damage exceeds a threshold, modulated by signal transduction pathways and oncogene expression.
Conclusions:
- Ara-C efficacy is determined by its metabolic activation, DNA incorporation, and induction of apoptosis.
- Understanding these regulatory levels is crucial for overcoming ara-C resistance.
- Further insights may lead to novel therapeutic strategies for improved leukemia treatment.